USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
PROFECTUS BIOSCIENCES, INC.
Address:
6411 Beckley St
BALTIMORE, MD 21224-
Phone:
N/A
URL:
N/A
EIN:
102057941
DUNS:
185576639
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,378,405.00 9
SBIR Phase II $7,138,338.00 3

Award List:

Enhancing DNA vaccines using modified Cholera Toxin A1 Subunit as an adjuvant

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$294,643.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Vaccination using plasmid DNA has the potential to provide enhanced safety and efficacy over conventional vaccines with increased stability, and accelerated product development. Unfortunately, vaccination of primates w ith DNA requires multiple inoculations… More

Rapamycin Enhanced Efficiency of Anti-HIV Antibodies

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$215,170.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This document contains proprietary information that Profectus BioSciences requests not be released to persons outside the Government, except for purposes of review and evaluation. Abstract Polyclonal and monoclonal ant ibody preparations were among the first… More

Rapamycin enhanced efficacy of small-molecule HIV entry inhibitors

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$293,564.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Newer approaches to the treatment of HIV infection seek to block the entry of the virus into the cell by targeting different proteins engaged in the entry process. Possible targets for entry inhibition include the HIV e nvelope (Env) glycoproteins gp120 and gp41,… More

Universal Influenza DNA vaccine with Novel Toll-Like Receptor Adjuvants

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$256,171.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The enhanced safety, stability, and accelerated product development generally provided by DNA vaccination make it an appealing approach to develop a universal influenza vaccine. Unfortunately, successful DNA vaccinati on of primates requires multiple… More

Preclinical Development of Full Length Single Chain

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$299,258.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The positive outcome of the RV144 Phase III vaccine trial (the Thai trial ) that tested an ALVAC-HIV/AIDSVAX B/E prime/boost protocol has prompted the field to refocus on humoral immunity as a means of achieving steril izing immunity. This has also renewed… More

Enhancing DNA vaccines using modified Bacterial Toxin A1 Subunits as adjuvants

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$2,447,584.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Cholera toxin (CT) and the related heat-labile enterotoxin (LT) are AB toxins with cell targeting B domains and enzymatically active A domains. The enzymatically active A1 domains of both CT (CTA1) and LT (LTA1) have de monstrated particular promise as genetic… More

Novel immune stimulating adjuvants for an HIV DNA Vaccine

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$283,473.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This document contains proprietary information that Profectus BioSciences requests not be released to persons outside the Government, except for purposes of review and evaluation. Abstract The enhanced safety, stability , and accelerated product development… More

Novel Mucosal Adjuvant for an HIV DNA Vaccine

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$212,099.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This document contains proprietary information that Profectus BioSciences requests not be released to persons outside the Government, except for purposes of review and evaluation. Abstract DNA vaccination is an appealin g approach for developing prophylactic and… More

Preclinical Development of Full Length Single Chain

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$1,990,562.00
Agency:
HHS
Principal Investigator:
Timothy R. Fouts – 443-743-1110
Abstract:
DESCRIPTION (provided by applicant): The positive outcome of the RV144 Phase III vaccine trial (the Thai trial ) that tested an ALVAC-HIV/AIDSVAX B/E prime/boost protocol has prompted the field to refocus on humoral immunity as a means of achieving sterilizing immunity. This has also renewed… More

Prime/Boost Vaccine to Prevent Hepatocellular Carcinoma

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$300,000.00
Agency:
HHS
Principal Investigator:
John H. Eldridge – 716-272-7000
Abstract:
DESCRIPTION (provided by applicant): This SBIR application proposes to pre-clinically evaluate a pDNA prime - rVSV boost HCV vaccine intended to improve the sustained virologic response (SVR) rate in patients being treated with current standard of care (SOC) therapy for chronic HCV infection. Of… More

Optimization of a DNA Subunit Regimen for an HIV Vaccine

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$224,027.00
Agency:
HHS
Principal Investigator:
Timothy R. Fouts – 443-743-1110
Abstract:
DESCRIPTION (provided by applicant): Our primary approach to develop an effective prophylactic vaccine against HIV utilizes a novel immunogen called the Full Length Single Chain (FLSC) that consists of gp120 derived from HIV-1(BaL) genetically linked via a20 amino acid linker to the D1D2 domains of… More

Optimization of a DNA Subunit Regimen for an HIV Vaccine

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$2,700,192.00
Agency:
HHS
Principal Investigator:
Timothy R. Fouts – 443-743-1110
Abstract:
DESCRIPTION (provided by applicant): Our primary approach to develop an effective prophylactic vaccine against HIV utilizes a novel immunogen called the Full Length Single Chain (FLSC) that consists of gp120 derived from HIV-1(BaL) genetically linked via a20 amino acid linker to the D1D2 domains of… More